Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 475 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR Research Says That Your Birth Order Can Shape Your Personality April 4, 2019 Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT... September 26, 2022 7 Practical Tips for Taking Long-Term Medication January 9, 2024 Scientists developing urine and blood tests to detect brain tumours July 23, 2021 Load more HOT NEWS Man Gets His First Haircut In 15 Years To Join The... Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... Pastor Opens Homeless Shelter And Moves In To Raise Money For...
